J Clin Oncol 27 (27): 4522-9, 2009.[PUBMED Abstract] Seidman AD, Berry D, Cirrincione C, et al.: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
J Clin Oncol 26 (10): 1642-9, 2008.[PUBMED Abstract] Gonzalez-Angulo AM, Hortobagyi GN: Optimal schedule of paclitaxel: weekly is better.
J Clin Oncol 26 (10): 1585-7, 2008.[PUBMED Abstract] Gradishar WJ, Tjulandin S, Davidson N, et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.